Arch Biopartners EBITDA 2021-2024 | ACHFF

Arch Biopartners ebitda from 2021 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Arch Biopartners EBITDA 2021-2024 | ACHFF

Arch Biopartners ebitda from 2021 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$76.5B
Zoetis (ZTS)$69.3B
Takeda Pharmaceutical (TAK)$47.9B
Daiichi Sankyo, - (DSNKY)$42.7B
BeOne Medicines - (ONC)$27.6B
Sandoz Group AG (SDZNY)$24.9B
Summit Therapeutics (SMMT)$18.9B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.4B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.3B
Stevanato Group S.p.A (STVN)$7.8B
Corcept Therapeutics (CORT)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.1B
Ionis Pharmaceuticals (IONS)$6.8B
Grifols, S.A (GRFS)$6.7B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.3B
Soleno Therapeutics (SLNO)$4.2B
Crinetics Pharmaceuticals (CRNX)$3.1B
Hypermarcas (HYPMY)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.5B
Centessa Pharmaceuticals (CNTA)$2B
BioCryst Pharmaceuticals (BCRX)$1.9B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B